Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Featured trial
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

500 mg every 4 weeks in patients with endometrial cancer, specifically either microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Additionally, every 3 week (Q3W) flat-dosing

endometrial carcinoma
cancer
primary cancer
measurable disease
  • 229 views
  • 14 Dec, 2020
  • 16 locations
None
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

cancer (mCRC) it appeared that only the small subgroup of patients with MSI-H tumors (microsatellite instability-high phenotype) had a clinically meaningful response to the anti-PD-1- L1 antibodies. In

  • 0 views
  • 26 Jan, 2021
  • 2 locations
None
Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)

The purpose of this study is to assess the efficacy and safety of pembrolizumab or co-formulated pembrolizumab/quavonlimab in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

  • 0 views
  • 27 Oct, 2021
  • 32 locations
None
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Additionally, every 3 week (Q3W) flat-dosing will be studied in an additional tumor agnostic cohort.

  • 340 views
  • 05 Aug, 2021
  • 143 locations
None
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

The purpose of this study is to test the safety of the study drug, pembrolizumab, and to find out how well it works to prevent cancer from coming back in people who have had a solid tumor surgically removed, but still have tumor cells in their blood. During the study, …

pembrolizumab
solid tumor
cancer
immunomodulator
serum bilirubin
  • 0 views
  • 15 May, 2021
  • 8 locations
None
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

This prospective, single-arm study is conducted to investigate the safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite instability-high

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer

This is a trial investigating the efficacy and safety of Toripalimab combined with bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite instability-high

  • 0 views
  • 08 Aug, 2021
  • 1 location
None
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD

  • 1 views
  • 29 Aug, 2021
  • 1 location
None
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma MSI-H dMMR or NSCLC

instability-high (MSI-H) or mismatch-repair deficient (dMMR) cancer, or Non-Small Cell Lung Cancer (NSCLC)

  • 0 views
  • 23 Aug, 2021
  • 1 location
None
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317). Efficacy and safety will be assessed. A short description of the clinical study

  • 1 views
  • 24 Mar, 2021
  • 1 location